Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.
- Publication date
- 1 January 2020
- Publisher
- AMER SOC CLINICAL ONCOLOGY